Global Medical Department, Angelini Pharma S.p.A., Rome, Italy.
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Brain Behav. 2022 Mar;12(3):e2485. doi: 10.1002/brb3.2485. Epub 2022 Feb 9.
The effect of switching from lithium immediate release (Li-IR) to lithium prolonged release (Li-PR) on lithium-induced tremor after 1 and 12 weeks of treatment was evaluated in a randomized, multicenter, open trial, in bipolar patients from the participating sites with a tremor severity ≥2 (Udvalg for Kliniske Undersøgelser [UKU] rating scale) despite optimal lithium titration.
The primary endpoint was the evaluation of tremor by means of the UKU scale after 1 week of treatment. Secondary endpoints included manic Young Mania Rating Scale (YMRS) and depressive symptoms (Montgomery-Asberg Depression Rating Scale), a global assessment of the patient's status (Clinical Global Impression), polyuria/polydipsia (UKU item 3.8) and patient-reported outcomes.
Owing to difficulties in including suitable patients the enrollment phase was closed when 73 patients were randomized. Notwithstanding the lower number of patients, in the modified intention-to-treat population (n = 70) the primary endpoint was statistically significant: tremor improved after 1 week in 62.9% in Li-PR group against 20.0% of patients in Li-IR group (p = .0006; two-tailed Fisher's exact test). The difference remained statistically significant after 4 (p = .0031) and 12 weeks (p = .0128). The same analysis performed in the PP population confirmed these results. Among the secondary endpoints, only the factor convenience of the treatment satisfaction questionnaire showed a statistically significant difference between groups. There were no apparent differences in the safety profile of the two formulations.
This study is the first comparative documentation of a potential benefit of the prolonged-release formulation in reducing the symptom tremor, a well-known adverse effect of lithium therapy. Indeed, the study results should be interpreted taking into account the sample size lower than planned.
在一项随机、多中心、开放性试验中,评估在锂即刻释放(Li-IR)转换为锂持续释放(Li-PR)后 1 周和 12 周时,锂诱导震颤在最佳锂滴定后仍≥2 分(Udvalg for Kliniske Undersøgelser [UKU] 评分量表)的双相患者中的效果。
主要终点是治疗 1 周后通过 UKU 量表评估震颤。次要终点包括躁狂 Young 躁狂评定量表(YMRS)和抑郁症状(Montgomery-Asberg 抑郁评定量表)、患者状态的总体评估(临床总体印象)、多尿/多饮(UKU 项目 3.8)和患者报告的结果。
由于难以纳入合适的患者,当 73 名患者被随机分组时,入组阶段关闭。尽管患者人数较少,但在修改后的意向治疗人群(n=70)中,主要终点具有统计学意义:在 Li-PR 组中,62.9%的患者在 1 周后震颤改善,而 Li-IR 组中只有 20.0%的患者(p=0.0006;双侧 Fisher 精确检验)。在 4 周(p=0.0031)和 12 周(p=0.0128)时差异仍具有统计学意义。在 PP 人群中进行的相同分析证实了这些结果。在次要终点中,只有治疗满意度问卷的便利性因素在组间具有统计学差异。两种制剂的安全性特征没有明显差异。
这项研究是首次比较性地记录了持续释放制剂在减少锂治疗的已知不良反应震颤症状方面的潜在益处。事实上,应该考虑到低于计划的样本量来解释研究结果。